Log In
BCIQ
Print this Print this
 

Viaskin rPT

  Manage Alerts
Collapse Summary General Information
Company DBV Technologies S.A.
DescriptionBooster vaccine comprising genetically detoxified recombinant pertussis toxin (rPT) delivered by Viaskin epicutaneous patch
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationPertussis
Indication DetailsBooster vaccination against Bordetella pertussis (whooping cough)
Regulatory Designation
PartnerBioNet-Asia Co. Ltd.;
University of Geneva

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today